AAI/CML Invests in DE Dietrich Agitated Filter Dryer
News Dec 29, 2015
AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. (AAI/CML) have announced that it has upgraded its small molecule manufacturing capabilities at its site in Weert, Netherlands with the installation of a DE Dietrich Agitated Filter Dryer for controlled isolation of Intermediates and Active Pharmaceutical Ingredients (APIs).
The filter dryer, first introduced early this year, provides a completely closed system unit for isolation and drying, which minimizes operator exposure and provides a safer manufacturing environment.
“The investment in this technology has improved containment around isolation, enhanced the safety of our operating environment, and helped increase yields. Our highly active compounds can also be processed using this filter dryer with ancillary equipment, for customers that need additional protection for Occupational Exposure Limits (OELs),” stated Ted Dolan, Chief Operating Officer. “We are pleased to continue to offer more options for customers with our expanding capabilities.”
The DE Dietrich Agitated Filter Dryer also provides packaging efficiencies and the ability to re-dissolve using a second solvent within one system. The unit boasts a useful volume of 490 Liters, cake volume of 180 Liters and nominal filtration area of 0.6m2.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018